SCHEMBL10315354

SCHEMBL10315354

c1ccc(-c2nnc(-c3ccc(N(c4ccccc4)c4ccc(-c5nc6cc(-c7cccc8ccccc78)c(-c7cccc8ccccc78)cc6nc5-c5ccc(N(c6ccccc6)c6ccc(-c7nnc(-c8ccccc8)o7)cc6)cc5)cc4)cc3)o2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 2/20 0.47
▸ ALDH1A1 P00352 10/20 0.46
▸ RAB9A P51151 10/20 0.46
▸ KDM4E B2RXH2 7/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ ATM Q13315 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ MAPT P10636 4/20 0.42
▸ TSHR P16473 6/20 0.41
▸ HPGD P15428 5/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ SMN1; SMN2 Q16637 8/20 0.39
▸ NPC1 O15118 8/20 0.39
▸ GAA P10253 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TP53 P04637 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10315097 1.00 ATR (0.47) ATRALDH1A1RAB9AKDM4EHSD17B10
SCHEMBL12722087 0.91 RAB9A (0.52) ATRALDH1A1RAB9AKDM4EHSD17B10
SCHEMBL12721926 0.91 RAB9A (0.52) ATRALDH1A1RAB9AKDM4EHSD17B10
SCHEMBL10315091 0.90 ALDH1A1 (0.50) ATRALDH1A1RAB9AKDM4EHSD17B10
SCHEMBL10315127 0.90 ATR (0.47) ATRALDH1A1RAB9AKDM4EHSD17B10
SCHEMBL10315334 0.88 ALDH1A1 (0.51) ATRALDH1A1RAB9AKDM4EHSD17B10
SCHEMBL10315346 0.88 ATR (0.43) ATRALDH1A1RAB9AKDM4EHSD17B10
SCHEMBL10315100 0.88 ATR (0.43) ATRALDH1A1RAB9AKDM4EHSD17B10
SCHEMBL6725306 0.88 KDM4E (0.40) ALDH1A1KDM4EHSD17B10ATMMAPT
SCHEMBL6725272 0.88 KDM4E (0.40) ALDH1A1KDM4EHSD17B10ATMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2067778-B1 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LAB (JP) 2016-08-17 — — EP disclosed
US-8216696-B2 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-07-10 — — US disclosed
US-8216696-B2 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-07-10 — — US disclosed
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-18 — — US disclosed
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-18 — — US disclosed
EP-2067778-A1 Quinoxaline derivative, and light emitting element, licht emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-06-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SLC1A2, SLC18A2, SLC18A3 ATR 2359/4885ALDH1A1 1610/4885RAB9A 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback